Skip to content
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

International Stem Cell Corp. ISCO

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$9.1M
▲ 0.2% YoY
$-418,000
$-35,000

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 9.1M
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2025 · Revenue 9.1 · Net income -0.4
5M10M-5M-10M
2007201020132016201920222025
Compound annual growth
+3.6%
+5.0%
+1.9%
+12.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +5.0% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−5 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -2.9% · Net -4.6%
-500%
200720162025
ROE
FY2018 · ROE -92.6%
-1000%-2000%
200720162025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -74%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -0.0
0.3M0.6M-2.5M-5.0M
200720162025

Total assetsUSD 4.8M
EquityUSD -4.1M
CashUSD 993,000.00
Current ratio0.74×

Equity funds -84% of total assets.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ISCO, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
EBITDA $B−0.00.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
Income tax $B0.00.0◌◌◌◌◌0.00.00.00.00.00.0◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌◌◌◌
EPS, diluted $−0.05−0.03−0.02−0.04−0.11−0.36−0.57−0.33−1.46−0.34−2.26−10.34−0.09−0.13−0.12−0.21◌◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————————
ROE %———————−92.6−220.4−42.8−275.2———−203.5——−2037.5−2864.2
Shares out B0.010.010.010.010.010.010.010.010.010.000.000.000.150.090.080.07◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 66 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007

Share this section

Download image